Congress materials
- Tislelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as First-Line Treatment for Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma: PD-L1 Tumor Area Positivity Score ≥1% Subgroup Analysis of RATIONALE-306
- Treatment Patterns in Advanced Gastric Cancer Across Racial and Ethnic Groups in the Immunotherapy Era: A Retrospective Claims Data Analysis in the United States
- Zanidatamab + Chemotherapy ± Tislelizumab for First-Line HER2-Positive Locally Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma: Primary Analysis From HERIZON-GEA-01
- Changes in Real-World Treatment Patterns Over Time by Patient Characteristics and Time Burden of Treatment in CLL/SLL
- Chemo ± Immunotherapy Remains Utilized for Chronic Lymphocytic Leukemia in Real-World Practice: Unmet Needs, Treatment Patterns, and Age Disparities in the United States
- Evaluation of Factors From Established Prognostic Models in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Zanubrutinib: A Post-Hoc Analysis of Two Phase 3 Studies (SEQUOIA and ALPINE)
- Impact of Testing for Genetic Markers on Treatment Selection and Clinical Outcomes Among Patients With Chronic Lymphocytic Leukemia
- Long-Term Results of Patients Receiving Zanubrutinib in the Phase 3 ALPINE Study Confirm Sustained Benefit of Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (R/R CLL/SLL): Up to 6 Years of Follow-Up With the Long-Term Extension (LTE1)
- Matching-Adjusted Indirect Comparison of the Efficacy of Zanubrutinib Versus Ibrutinib for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
- Mediators of Racial and Ethnic Inequities in Access to Front-Line Therapies for Chronic Lymphocytic Leukemia in the United States: A Real-World Evidence Study
- Number Needed to Treat to Avoid Progression or Death: Zanubrutinib vs Other Covalent Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia
- Outcomes During BTKi Treatment for Chronic Lymphocytic Leukemia: Insights From Remote Therapeutic Monitoring
- Progression-Free Survival in Patients With Low Health-Related Quality of Life Treated With Zanubrutinib Versus Ibrutinib Monotherapy: Post Hoc Analysis of the ALPINE Trial
- Real-World Treatment Patterns and Biomarker Utilization Among Patients Aged ≥65 Years With CLL/SLL From 2020 to 2024
- Real-World Treatment Patterns and Patient Characteristics of Venetoclax Combination Time-Limited Therapy for Chronic Lymphocytic Leukemia
- Sustained Efficacy of Zanubrutinib (zanu) vs Bendamustine + Rituximab (BR) in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN SLL/CLL) With Continued Favorable Survival In Non-Randomized Patients (pts) With del(17p): 6-Year Follow-Up in the Phase 3 SEQUOIA Study
- Symptom-Based Progression-Free Survival (S-PFS) as a Clinically Relevant and Patient-Centric Endpoint in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results From the ALPINE Trial
- Treatment Patterns and Outcomes Among Patients Treated With Second-Generation BTK Inhibitors in CLL
- Zanubrutinib + Venetoclax for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Patients With del(17p) and/or TP53 Mutation and Unmutated Immunoglobulin Heavy-Chain Variable Status: 3 Year Results From SEQUOIA Arm D
- Zanubrutinib Is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients With B-Cell Malignancies: A Long-Term Follow-Up
- Estimating the Cardiac Deaths Associated With Treating Chronic Lymphocytic Leukemia With Ibrutinib Versus Zanubrutinib in the United States
- Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia
- Outcomes, Inequities, and Access to Front-Line Preferred Therapies for Chronic Lymphocytic Leukemia in the United States: A Real-World Evidence Study
- Risk of Second Primary Malignancies in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving First-Line Therapy: A Real-World Study
- A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B-Cell Lymphoma
- A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib Versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL)
- Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients With Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses From the SEQUOIA Study
- Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared Decision-Making
- Real-World Bruton Tyrosine Kinase Inhibitor Use and Clinical Outcomes Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Real-World Burden of Disease, Treatment Patterns and Outcomes in Patients With Mantle Cell Lymphoma (MCL)
- Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line Bruton Tyrosine Kinase Inhibitor Therapy in Chronic Lymphocytic Leukemia: Age-Related Disparity
- Real-World Zanubrutinib Treatment Patterns in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Among US Community Oncology Patients With Prior Acalabrutinib Therapy
- Risk of Infections in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving First-Line Treatment: A Real-World Study
- Select Adverse Events of Interest With Zanubrutinib vs Fixed-Duration Combination of Venetoclax + Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia
- Comparing Real-World Treatment Patterns and Outcomes of Zanubrutinib and Acalabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma at University of California Academic Health Centers
- Evaluating Uptake of Targeted Agents by Race/Ethnicity in Patients Receiving First-Line Treatment for Chronic Lymphocytic Leukemia
- Comparative Efficacy and Safety of Tislelizumab vs Other Anti–PD-1 Treatments in First-Line Gastric or Gastroesophageal Junction Cancer: A Network Meta-Analysis
- Patient-Reported Outcome-Based Deterioration Predicts Overall Survival in Patients with Advanced Gastric Adenocarcinoma with PD-L1 Score of ≥5%: Post Hoc Analysis from the RATIONALE-305 Trial
- Tislelizumab (TIS) + Chemotherapy (CT) vs Placebo (PBO) + CT in Patients (pts) With Locally Advanced (LA) Esophageal Squamous Cell Carcinoma (ESCC): RATIONALE-306 Subgroup Analysis
- Comparative Efficacy of Zanubrutinib Versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)
- Efficacy of Continuous Zanubrutinib vs Fixed-Duration Venetoclax in Combination With Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
- Real-World Comparative Effectiveness of First-Line Bruton Tyrosine Kinase Inhibitors in Patients With Chronic Lymphocytic Leukemia
- Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Age-Related Disparity
- Real-World Zanubrutinib Treatment Patterns in Mantle Cell Lymphoma Among US Community Oncology Patients With Prior Bruton Tyrosine Kinase Inhibitor Therapy
- Risk of Hypertension in Patients Newly Diagnosed With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Treated With Covalent Bruton Tyrosine Kinase Inhibitors: A Real-World Study
- Combination of Zanubrutinib (zanu) + Venetoclax (ven) for Treatment-Naive (TN) CLL/SLL: Results From SEQUOIA Arm D
- Final Analysis of Multicenter, Open-Label, Phase 2 Study Evaluating the Efficacy and Safety of Tislelizumab (TIS) in Combination With Fruquintinib (F) in Patients (pts) With Selected Solid Tumors
- SEQUOIA 5-year Follow-Up (Arm C): Zanubrutinib in Patients With del(17p) and Treatment-Naive CLL/SLL
- SEQUOIA 5-Year Follow-Up of Arm C: Frontline Zanubrutinib Monotherapy In del(17p) Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Serious Infections in Patients With CLL/SLL Treated With Combination Venetoclax and Obinutuzumab Compared With Those Treated With Zanubrutinib: A Real-World Study
- Tislelizumab (TIS; BGB-A317) Plus Chemotherapy (CT)/Chemoradiotherapy (CRT) as Positron Emission Tomography (PET)-Guided Neoadjuvant (n) Treatment for Resectable Esophageal Squamous Cell Carcinoma (R-ESCC): RATIONALE-213 Final Analysis
- Treatment Preferences of Patients, Caregivers, and Physicians in Follicular Lymphoma (FL): A Global Discrete-Choice Experiment (DCE) Study
- Comparative Efficacy of Zanubrutinib Plus Obinutuzumab Versus Last Prior Treatment in Relapsed/Refractory Follicular Lymphoma: Growth Modulation Index Analysis From ROSEWOOD Study
- Real-world Bruton Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes Among Patients With CLL/SLL in US Community Oncology Practices
- Zanubrutinib Is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients With B-Cell Malignancies